Viral Inactivation Market Report 2021-2031

Where the Global Viral Inactivation market is heading? If you are involved in this industry you must read this newly updated report. Visiongain’s report shows you the potential revenue streams to 2031, assessing data, trends, opportunities and business prospects there.

SKU: PHA0965 Category: Therapeutic Drugs Tag: PHA0965 Code: PHA0965Pages: 194

Download Sample Form

"*" indicates required fields

Name*

Company*

Designation*

Job Title

Industry

Email*

Phone*

Address*

This field is hidden when viewing the form

Report Title

This field is hidden when viewing the form

Sample url

← Back to category Therapeutic Drugs

Description

Global Viral Inactivation Market-our new study reveals current trends, technological advancements, and predicted revenues

Discover how to stay ahead

Our 190+ page report provides 150+ tables, 150+ charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our study lets you assess forecasted sales at overall world market and regional level. See financial performance of companies, trends, opportunities, and revenue growth. Much opportunity remains in this growing Global Viral Inactivation market. See how to exploit the opportunities.

Forecasts to 2031 and other analyses reveal the commercial prospects

, In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares, key player positioning, and an exhaustive product portfolio comparison of key vendors

, You find original analyses, with business outlooks and developments which would be useful to tap potential business areas for key players

, Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges, SWOT analysis), product profiles and commercial developments.

Report Scope

Global Viral Inactivation market 2021-2031 is segmented on the basis of Product, Application, End Users and Geography.

• Revenue and growth forecasts from 2021 to 2031 for the Global Viral Inactivation Market by Product:

,Kits and Reagents

, Systems

, Services

• Revenue and growth forecasts from 2021 to 2031 for the Global Viral Inactivation Market by Application:

,Vaccines and Therapeutics

, Stem Cell Products

, Blood and Blood Products

,Tissue and Tissue Products

,Cellular and Gene Therapy

• Revenue and growth forecasts from 2021 to 2031 for the Global Viral Inactivation Market by End User:

,Pharmaceutical and Biotechnology Companies

,CROs

, Academic and Research Institutes

,Others

• Revenue and growth forecasts from 2021 to 2031 for the Global Viral Inactivation Market by Region:

, North America: US, Canada

, Europe: Germany, UK, Italy, France, Spain, Rest of Europe

, Asia-Pacific: China, India, Japan, Australia, Rest of Asia-Pacific

, Latin America: Brazil, Mexico, and Rest of Latin America

, Middle East & Africa: GCC, South Africa, Rest of MEA

• Our study discusses the selected leading companies that are the major players in the Global Viral Inactivation industry:

, Danaher Corporation

,Merck KGAA

, Parker Hannifin Corporation

, Sartorius AG

, Rad Source Technologies

, Viral Inactivated Plasma Systems SA

, Cerus Corporation

, Clean Cells Inc.

, Texcell, Inc.

, Wuxi Pharmatech (Cayman) Inc.

,Charles River Laboratories

,BioReliance

How the Global Viral Inactivation Market report helps you

In summary, our 190+ page report provides you with the following knowledge:
, Revenue forecasts to 2031 for each of the above mentioned segments each forecasted at a global and regional level, growth of all segments on regional level helps to understand most lucrative segment.

, Revenue forecasts to 2031 for 5 regional and 10 key national markets , the report highlights market growth prospects for key countries such as the U.S., Canada, Germany, UK, France, Italy, Spain, China, Japan, and India. The report also highlights growth potential in Central & South America as well as Middle East & Africa.

, Prospects for established firms and those seeking to enter the market, including company profiles for over 10 of the major companies involved in the Global Viral Inactivation market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

COVID 19 Impact & Recovery Analysis on the Market

Currently, COVID-19 (Coronavirus) is prevalent across the globe. Many companies are underway to discover a vaccine, or therapeutics which can prevent or cure the COVID-19 virus. According to the World Health Organization, as of 13th September 2020, there were over 28,637,952 confirmed cases of COVID-19, with more than 917,417 deaths, globally.

The COVID-19 disease is continuously disrupting the growth of various markets. However, the immediate effect of the pandemic is different. Some industries will register a drop in demand, various other markets will remain unchanged and display a promising growth opportunities. The healthcare centers, such as hospitals and diagnostic labs, have been investing heavily in maintaining the supply of essential equipment and drugs. Due to lockdown across the globe, people were unable to reach healthcare facilities and non-urgent procedures were advised to put hold which impacted the healthcare industry a lot.

Due to COVID 19 pandemic patients were reluctant in visiting hospitals or clinics for their treatments and preferred virtual doctor visits. Lockdown across the globe due to the pandemic led to the delay of procedures which were not urgent. These factors negatively impacted the Viral Inactivation market for limited period of time. However, slowly the situation is getting back to normal everywhere and the market discussed is expected to increase in future.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Global Viral Inactivation market and leading companies. You will find data, trends and predictions.

The Global Viral Inactivation Market 2021-2031 report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Global Viral Inactivation industry.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Viral Inactivation Market Report 2021-2031: Forecasts by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed , order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated VISIONGAIN Reports
1.8. About VISIONGAIN
2. Introduction to the Viral Inactivation Market
2.1. Viral InactivationMarket Definition
2.2. Application Submarkets Definitions
2.3. Method Submarkets Definitions
2.4. Product Submarkets Definitions
3. Viral Inactivation Market Overview
3.1. Global Viral Inactivation Market Size and Forecast by Region
3.2. Global Viral Inactivationl Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Growing Figure of New Medicine Promotions
3.3.1.2. Growing Administration Care for Pharmaceutical and Biotechnology Trades
3.3.2. Market Restraints/Challenges
3.3.2.1. High Grade of Alliance to Act as a Main Fence for Original Applicants
3.3.3. Opportunities
3.3.3.1. Growing Medical Outsourcing
3.3.4. Trends
3.3.4.1. Trends 1
3.4. SWOT Analysis
3.4.1. Strengths
3.4.1.1. Strength 1
3.4.2. Weaknesses
3.4.2.1. Weakness 1
3.4.3. Opportunities
3.4.3.1. Opportunity 1
3.4.4. Threats
3.4.4.1. Threat 1
3.5. Porter's Five Forces Analysis
3.5.1. Competitive Rivalry
3.5.2. Supplier Power
3.5.3. Buyer Power
3.5.4. Threat of Substitution
3.5.5. Threat of New Entry
4. GlobalViral Inactivation Market Analysis and Forecast 2021-2031, by Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Blood & Blood Products
4.3. Cellular & Gene Therapy Products
4.4. Stem Cell Products
4.5. Tissue & Tissue Products
4.6. Vaccines and Therapeutics
5. GlobalViral Inactivation Market Analysis and Forecast, 2021-2031 by Method (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.2. Solvent Detergent Method
5.3. PasteurizationMethod
5.4. Other viral inactivation method
6. Global Viral Inactivation Market Analysis and Forecast, 2021-2031 by Product (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. Kits and Reagents
6.3. Services
6.4. Viral Inactivation system and Accessories
7. Global Viral Inactivation Market Analysis and Forecast, 2021-2031 by End User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Pharmaceutical and Biotechnology Companies
7.3. Contract Research Organizations
7.4. Academic Research Institutes
8. North AmericaViral Inactivation Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. North America Viral Inactivation Size and Forecast byApplication
8.3. North America Viral Inactivation Market Size and Forecast by Method
8.4. North America Viral InactivationMarket Size and Forecast by Product
8.5. North America Viral InactivationMarket Size and Forecast byEnd User
8.6. U.S Viral Inactivation. Market
8.7. Canada Viral Inactivation Market
9. EuropeViral Inactivation Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Europe Viral InactivationMarket Size and Forecast by Application
9.3. Europe Viral InactivationMarket Size and Forecast by Method
9.4. Europe Viral InactivationSize and Forecast by Product
9.5. Europe Viral InactivationSize and Forecast by End User
9.6. UK Viral Inactivation Market
9.7. Germany Viral InactivationMarket
9.8. France Viral Inactivation Market
9.9. Rest of Europe Viral InactivationMarket
10. Asia Pacific Viral Inactivation Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Asia Pacific Viral Inactivation Market Size and Forecast by Application
10.3. Asia Pacific Viral Inactivation Market Size and Forecast by Method
10.4. Asia Pacific Viral InactivationMarket Size and Forecast by Product
10.5. Asia Pacific Viral InactivationMarket Size and Forecast by End User
10.6. China Viral InactivationMarket
10.7. India Viral Inactivation Market
10.8. Japan Viral InactivationMarket
10.9. Rest of Asia Pacific Viral InactivationMarket
11. Latin AmericaViral Inactivation Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Latin America Viral Inactivation Market Size and Forecast by Application
11.3. Latin America Viral Inactivation Market Size and Forecast by Method
11.4. Latin America Viral Inactivation Market Size and Forecast by Product
11.5. Latin America Viral Inactivation Market Size and Forecast by End User
11.6. Brazil Viral InactivationMarket
11.7. Mexico Viral Inactivation Market
11.8. Rest of Latin America Viral InactivationMarket
12. MEAViral Inactivation Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. MEA Viral InactivationMarket Size and Forecast by Application
12.3. MEA Viral InactivationMarket Size and Forecast by Method
12.4. MEA Viral InactivationMarket Size and Forecast by Product
12.5. MEA Viral InactivationMarket Size and Forecast by End User
12.6. GCC Viral Inactivation Market
12.7. South Africa Viral Inactivation Market
12.8. Rest of MEA Viral InactivationMarket
13. Companies in theViral Inactivation Market
13.1. Danaher Corporation
13.1.1. Company Snapshot
13.1.2. Company Overview
13.1.3. Financial Performance (2015-2019)
13.1.3.1. Net Revenue
13.1.3.2. Gross Profit
13.1.3.3. Geographical Revenue, 2019
13.1.4. Product Offerings
13.1.5. Recent Initiatives (2017-2019)
13.2. Merck KGAA.
13.2.1. Company Snapshot
13.2.2. Company Overview
13.2.3. Financial Performance (2015-2019)
13.2.3.1. Net Revenue
13.2.3.2. Gross Profit
13.2.3.3. Geographical Revenue, 2019
13.2.4. Product Offerings
13.2.5. Recent Initiatives (2017-2019)
13.3. Parker Hannifin Corporation
13.3.1. Company Snapshot
13.3.2. Company Overview
13.3.3. Financial Performance (2015-2019)
13.3.3.1. Net Revenue
13.3.3.2. Gross Profit
13.3.3.3. Geographical Revenue, 2019
13.3.4. Product Offerings
13.3.5. Recent Initiatives (2017-2019)
13.4. Sartorius AG
13.4.1. Company Snapshot
13.4.2. Company Overview
13.4.3. Financial Performance (2015-2019)
13.4.3.1. Net Revenue
13.4.3.2. Gross Profit
13.4.3.3. Geographical Revenue, 2019
13.4.4. Product Offerings
13.4.5. Recent Initiatives (2017-2019)
13.5. SGS SA
13.5.1. Company Snapshot
13.5.2. Company Overview
13.5.3. Financial Performance (2015-2019)
13.5.3.1. Net Revenue
13.5.3.2. Gross Profit
13.5.3.3. Geographical Revenue, 2019
13.5.4. Product Offerings
13.5.5. Recent Initiatives (2017-2019)
13.6. Charles River Laboratories International, Inc.
13.6.1. Company Snapshot
13.6.2. Company Overview
13.6.3. Financial Performance (2015-2019)
13.6.3.1. Net Revenue
13.6.3.2. Gross Profit
13.6.3.3. Geographical Revenue, 2019
13.6.4. Product Offerings
13.6.5. Recent Initiatives (2017-2019)
13.7. Rad Source Technologies, Inc.
13.7.1. Company Snapshot
13.7.2. Company Overview
13.7.3. Financial Performance (2015-2019)
13.7.3.1. Net Revenue
13.7.3.2. Gross Profit
13.7.3.3. Geographical Revenue, 2019
13.7.4. Product Offerings
13.7.5. Recent Initiatives (2017-2019)
13.8. Texcell, Inc.
13.8.1. Company Snapshot
13.8.2. Company Overview
13.8.3. Financial Performance (2015-2019)
13.8.3.1. Net Revenue
13.8.3.2. Gross Profit
13.8.3.3. Geographical Revenue, 2019
13.8.4. Product Offerings
13.8.5. Recent Initiatives (2017-2019)
13.9. Wuxi Pharmatech (Cayman) Inc.
13.9.1. Company Snapshot
13.9.2. Company Overview
13.9.3. Financial Performance (2015-2019)
13.9.3.1. Net Revenue
13.9.3.2. Gross Profit
13.9.3.3. Geographical Revenue, 2019
13.9.4. Product Offerings
13.9.5. Recent Initiatives (2017-2019)
13.10. Viral Inactivated Plasma Systems SA
13.10.1. Company Snapshot
13.10.2. Company Overview
13.10.3. Financial Performance (2015-2019)
13.10.3.1. Net Revenue
13.10.3.2. Gross Profit
13.10.3.3. Geographical Revenue, 2019
13.10.4. Product Offerings
13.10.5. Recent Initiatives (2017-2019)
13.11. Other Notable Players
14. Conclusion
15. Glossary
Associated VISIONGAIN Reports
VISIONGAIN Report Sales Order Form
Appendix A
About VISIONGAIN
Appendix B
VISIONGAIN report evaluation form

LIST OF TABLES
Table No 1: Viral Inactivation Market Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 2: Viral Inactivation Market Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 3: Viral Inactivation Market Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 4: Viral Inactivation Market Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 5: Viral Inactivation Market Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 6: Viral Inactivation Market Drivers & Restraints 2020
Table No 7: Viral Inactivation Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 8: Viral Inactivation Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 9: Viral Inactivation Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 10: Viral Inactivation Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 11: Viral Inactivation Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 12: Blood & Blood Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 13: Blood & Blood Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 14: Blood & Blood Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 15: Blood & Blood Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 16: Blood & Blood Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 17: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 18: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 19: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 20: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 21: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 22: Stem Cell Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 23: Stem Cell Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 24: Stem Cell Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 25: Stem Cell Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 26: Stem Cell Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 27: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 28: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 29: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 30: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 31: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 32: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 33: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 34: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 35: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 36: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 37: Viral Inactivation Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 38: Viral Inactivation Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 39: Viral Inactivation Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 40: Viral Inactivation Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 41: Viral Inactivation Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 42: Solvent Detergent Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 43: Solvent Detergent Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 44: Solvent Detergent Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 45: Solvent Detergent Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 46: Solvent Detergent Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 47: Pasteurization Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 48: Pasteurization Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 49: Pasteurization Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 50: Pasteurization Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 51: Pasteurization Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 52: Viral Inactivation Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 53: Viral Inactivation Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 54: Viral Inactivation Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 55: Viral Inactivation Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 56: Viral Inactivation Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 57: Kits and Reagents Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 58: Kits and Reagents Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 59: Kits and Reagents Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 60: Kits and Reagents Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 61: Kits and Reagents Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 62: Services Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 63: Services Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 64: Services Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 65: Services Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 66: Services Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 67: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 68: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 69: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 70: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 71: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 72: End User Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 73: End User Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 74: End User Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 75: End User Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 76: End User Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 77: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 78: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 79: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 80: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 81: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 82: Contract Research Organizations Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 83: Contract Research Organizations Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 84: Contract Research Organizations Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 85: Contract Research Organizations Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 86: Contract Research Organizations Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 87: Academic Research Institutes Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Table No 88: Academic Research Institutes Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 89: Academic Research Institutes Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 90: Academic Research Institutes Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 91: Academic Research Institutes Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 92: Regional Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 93: Regional Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 94: Regional Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 95: Regional Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 96: Regional Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 97: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 98: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 99: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 100: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 101: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 102: North America Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 103: North America Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 104: North America Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 105: North America Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 106: North America Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 107: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 108: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 109: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 110: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 111: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 112: North America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 113: North America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 114: North America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 115: North America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 116: North America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 117: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 118: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 119: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 120: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 121: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 122: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 123: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 124: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 125: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 126: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 127: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 128: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 129: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 130: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 131: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 132: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 133: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 134: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 135: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 136: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 137: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 138: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 139: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 140: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 141: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 142: Europe Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 143: Europe Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 144: Europe Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 145: Europe Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 146: Europe Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 147: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 148: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 149: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 150: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 151: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 152: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 153: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 154: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 155: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 156: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 157: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 158: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 159: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 160: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 161: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 162: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 163: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 164: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 165: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 166: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 167: Asia Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 168: Asia Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 169: Asia Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 170: Asia Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 171: Asia Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 172: Asia Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 173: Asia Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 174: Asia Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 175: Asia Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 176: Asia Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 177: Asia Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 178: Asia Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 179: Asia Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 180: Asia Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 181: Asia Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 182: Asia Pacific Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 183: Asia Pacific Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 184: Asia Pacific Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 185: Asia Pacific Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 186: Asia Pacific Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 187: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 188: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 189: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 190: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 191: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 192: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 193: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 194: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 195: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 196: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 197: India Military Aircraft Fleet (Aircraft Application, Number of Aircraft)
Table No 198: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 199: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 200: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 201: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 202: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 203: Japan Military Aircraft Fleet (Aircraft Application, Number of Aircraft)
Table No 204: RoAPAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 205: RoAPAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 206: RoAPAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 207: RoAPAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 208: RoAPAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 209: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 210: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 211: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 212: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 213: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 214: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 215: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 216: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 217: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 218: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 219: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 220: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 221: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 222: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 223: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 224: Latin America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 225: Latin America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 226: Latin America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 227: Latin America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 228: Latin America Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 229: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 230: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 231: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 232: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 233: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 234: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 235: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 236: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 237: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 238: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 239: Rest of Latin America Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 240: Rest of Latin America Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 241: Rest of Latin America Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 242: Rest of Latin America Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 243: Rest of Latin America Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 244: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 245: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 246: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 247: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 248: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 249: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 250: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 251: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 252: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 253: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 254: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 255: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 256: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 257: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 258: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 259: Middle East Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 260: Middle East Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 261: Middle East Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 262: Middle East Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 263: Middle East Viral Inactivation Market Forecast by End User 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 264: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 265: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 266: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 267: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 268: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 269: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 270: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 271: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 272: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 273: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 274: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (Before COVID)
Table No 275: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario V)
Table No 276: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario U)
Table No 277: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario W)
Table No 278: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %, CAGR %) (COVID - Scenario L)
Table No 279: Leading 10 Fiber Optic Network Companies (Ranking, Company, Latest Total Company Sales US $MN*, HQ)
Table No 280: Danaher Corporation. Profile (CEO, HQ, Founded, Website)
Table No 281: Danaher Corporation. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 282: Danaher Corporation. (Net Income 2016-2019 (US $Mn, AGR %)
Table No 283: Merck KGAA Profile (CEO, HQ, Founded, Website)
Table No 284: Merck KGAA (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 285: Merck KGAA (Net Income 2016-2019 (US $Mn, AGR %)
Table No 286: Parker Hannifin Corporation. Profile (CEO, HQ, Founded, Website)
Table No 287: Parker Hannifin Corporation. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 288: Parker Hannifin Corporation. (Net Income 2016-2019 (US $Mn, AGR %)
Table No 289: Sartorius AG. Profile (CEO, HQ, Founded, Website)
Table No 290: Sartorius AG. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 291: Sartorius AG. (Net Income 2016-2019 (US $Mn, AGR %))
Table No 292: SGS SA Profile (CEO, HQ, Founded, Website)
Table No 293: SGS SA Profile (Total Company Sales 2016-2019 (US $Mn, AGR %)
Table No 294: SGS SA Profile (Net Income 2016-2019 (US $Mn, AGR %))
Table No 295: Charles River Laboratories International, Inc Profile (CEO, HQ, Founded, Website)
Table No 296: Charles River Laboratories International, Inc (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 297: Charles River Laboratories International, Inc (Net Income 2016-2019 (US $Mn, AGR %))
Table No 298: Rad Source Technologies, Inc. Profile (CEO, HQ, Founded, Website)
Table No 299: Rad Source Technologies, Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 300: Rad Source Technologies, Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Table No 301: Texcell, Inc. Profile (CEO, HQ, Founded, Website)
Table No 302: Texcell, Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 303: Texcell, Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Table No 304: Wuxi Pharmatech (Cayman) Inc. (CEO, HQ, Founded, Website)
Table No 305: Wuxi Pharmatech (Cayman) Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 306: Wuxi Pharmatech (Cayman) Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Table No 307: Viral Inactivated Plasma Systems SA Profile (CEO, HQ, Founded, Website)
Table No 308: Viral Inactivated Plasma Systems SA (Total Company Sales 2016-2019 (US $Mn, AGR %))
Table No 309: Viral Inactivated Plasma Systems SA (Net Income 2016-2019 (US $Mn, AGR %))
Table No 310: Other Companies Viral Inactivation Market 2020 (Company, Location)

LIST OF FIGURES
Figure No 1: Viral Inactivation Market Application Overview
Figure No 2: Viral Inactivation Market Method Overview
Figure No 3: Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 4: Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 5: Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 6: Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 7: Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 8: Viral Inactivation Submarket Forecast by Application 2021-2031 (US $MN, Global AGR %) (Before COVID)
Figure No 9: Viral Inactivation Submarket Forecast by Application 2021-2031 (US $MN, Global AGR %) (COVID - Scenario V)
Figure No 10: Viral Inactivation Submarket Forecast by Application 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 11: Viral Inactivation Submarket Forecast by Application 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 12: Viral Inactivation Submarket Forecast by Application 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 13: Blood & Blood Products 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 14: Blood & Blood Products 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 15: Blood & Blood Products 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 16: Blood & Blood Products 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 17: Blood & Blood Products 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 18: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 19: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 20: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 21: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 22: Cellular & Gene Therapy Products Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 23: Stem Cell Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 24: Stem Cell Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 25: Stem Cell Products Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 26: Stem Cell Products Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 27: Stem Cell Products Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 28: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 29: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 30: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 31: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 32: Tissue & Tissue Products Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 33: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 34: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 35: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 36: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 37: Vaccines and Therapeutics Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 38: Viral Inactivation Submarket Forecast by Method 2021-2031 (US $MN, Global AGR %) (Before COVID)
Figure No 39: Viral Inactivation Submarket Forecast by Method 2021-2031 (US $MN, Global AGR %) (COVID - Scenario V)
Figure No 40: Viral Inactivation Submarket Forecast by Method 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 41: Viral Inactivation Submarket Forecast by Method 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 42: Viral Inactivation Submarket Forecast by Method 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 43: Solvent Detergent Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 44: Solvent Detergent Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 45: Solvent Detergent Method Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 46: Solvent Detergent Method Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 47: Solvent Detergent Method Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 48: Pasteurization Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 49: Pasteurization Method Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 50: Pasteurization Method Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 51: Pasteurization Method Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 52: Pasteurization Method Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 53: Viral Inactivation Submarket Forecast by Product 2021-2031 (US $MN, Global AGR %) (Before COVID)
Figure No 54: Viral Inactivation Submarket Forecast by Product 2021-2031 (US $MN, Global AGR %) (COVID - Scenario V)
Figure No 55: Viral Inactivation Submarket Forecast by Product 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 56: Viral Inactivation Submarket Forecast by Product 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 57: Viral Inactivation Submarket Forecast by Product 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 58: Kits and Reagents Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 59: Kits and Reagents Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 60: Kits and Reagents Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 61: Kits and Reagents Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 62: Kits and Reagents Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 63: Services Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 64: Services Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 65: Services Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 66: Services Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 67: Services Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 68: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 69: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 70: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 71: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 72: Viral Inactivation system and Accessories Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 73: Viral Inactivation Submarket Forecast by End User 2021-2031 (US $MN, Global AGR %) (Before COVID)
Figure No 74: Viral Inactivation Submarket Forecast by End User 2021-2031 (US $MN, Global AGR %) (COVID - Scenario V)
Figure No 75: Viral Inactivation Submarket Forecast by End User 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 76: Viral Inactivation Submarket Forecast by End User 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 77: Viral Inactivation Submarket Forecast by End User 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 78: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 79: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 80: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 81: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 82: Pharmaceutical and Biotechnology Companies Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 83: Contract Research Organizations Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 84: Contract Research Organizations Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 85: Contract Research Organizations Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 86: Contract Research Organizations Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 87: Contract Research Organizations Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 88: Academic Research Institutes Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (Before COVID)
Figure No 89: Academic Research Institutes Submarket Forecast 2021-2031 (US $Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 90: Academic Research Institutes Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario U)
Figure No 91: Academic Research Institutes Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario W)
Figure No 92: Academic Research Institutes Submarket Forecast 2021-2031 (US $MN, Global AGR %) (COVID - Scenario L)
Figure No 93: Regional Viral Inactivation Market Forecast 2021-2031 (Sales US $MN, Global AGR %)
Figure No 94: Regional Viral Inactivation Market Forecast 2021-2031 (Sales US $MN, Global AGR %) (COVID - Scenario V)
Figure No 95: Regional Viral Inactivation Market Forecast 2021-2031 (Sales US $MN, Global AGR %) (COVID - Scenario U)
Figure No 96: Regional Viral Inactivation Market Forecast 2021-2031 (Sales US $MN, Global AGR %) (COVID - Scenario W)
Figure No 97: Regional Viral Inactivation Market Forecast 2021-2031 (Sales US $MN, Global AGR %) (COVID - Scenario L)
Figure No 98: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 99: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 100: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 101: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 102: North America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 103: North America Viral Inactivation Market Forecast by Method2021-2031 (US $MN, AGR %)
Figure No 104: North America Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 105: North America Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 106: North America Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 107: North America Viral Inactivation Market Forecast by Method 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 108: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %)
Figure No 109: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 110: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 111: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 112: North America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 113: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 114: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 115: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 116: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 117: US Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 118: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %)
Figure No 119: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 120: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 121: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 122: Canada Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 123: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (Before COVID)
Figure No 124: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario V)
Figure No 125: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario U)
Figure No 126: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario W)
Figure No 127: Europe Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario L)
Figure No 128: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN) (Before COVID)
Figure No 129: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN) (COVID - Scenario V)
Figure No 130: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN) (COVID - Scenario U)
Figure No 131: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN) (COVID - Scenario W)
Figure No 132: Europe Viral Inactivation Market Forecast by Method 2021-2031 (US $MN) (COVID - Scenario L)
Figure No 133: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %)
Figure No 134: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 135: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 136: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 137: Europe Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 138: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 139: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 140: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 141: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 142: UK Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 143: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %)
Figure No 144: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 145: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 146: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 147: Germany Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 148: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %)
Figure No 149: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 150: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 151: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 152: France Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 153: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 154: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 155: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 156: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 157: Rest of Europe Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 158: Asia-Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (Before COVID)
Figure No 159: Asia-Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario V)
Figure No 160: Asia-Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario U)
Figure No 161: Asia-Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario W)
Figure No 162: Asia-Pacific Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario L)
Figure No 163: Asia-Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN)
Figure No 164: Asia-Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario V)
Figure No 165: Asia-Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario U)
Figure No 166: Asia-Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario W)
Figure No 167: Asia-Pacific Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario L)
Figure No 168: Asia-Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %)
Figure No 169: Asia-Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 170: Asia-Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 171: Asia-Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 172: Asia-Pacific Viral Inactivation Market Forecast by Product 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 173: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %)
Figure No 174: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 175: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 176: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 177: China Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 178: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %)
Figure No 179: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 180: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 181: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 182: India Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 183: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 184: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 185: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 186: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 187: Japan Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 188: Rest of APAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 189: Rest of APAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 190: Rest of APAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 191: Rest of APAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 192: Rest of APAC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 193: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN)
Figure No 194: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario V)
Figure No 195: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario U)
Figure No 196: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario W)
Figure No 197: Latin America Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario L)
Figure No 198: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN)
Figure No 199: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario V)
Figure No 200: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario U)
Figure No 201: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario W)
Figure No 202: Latin America Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario L)
Figure No 203: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN)
Figure No 204: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN) (COVID - Scenario V)
Figure No 205: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN) (COVID - Scenario U)
Figure No 206: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN) (COVID - Scenario W)
Figure No 207: Latin America Viral Inactivation Market Forecast by Product 2021-2031 (US $MN) (COVID - Scenario L)
Figure No 208: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 209: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 210: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 211: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 212: Brazil Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 213: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 214: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 215: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 216: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 217: Mexico Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 218: Rest of Latin America Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 219: Rest of Latin Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 220: Rest of Latin Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 221: Rest of Latin Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 222: Rest of Latin Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 223: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (Before COVID)
Figure No 224: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario V)
Figure No 225: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario U)
Figure No 226: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario W)
Figure No 227: Middle East Viral Inactivation Market Forecast by Application 2021-2031 (US $MN) (COVID - Scenario L)
Figure No 228: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (Before COVID)
Figure No 229: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario V)
Figure No 230: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario U)
Figure No 231: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario W)
Figure No 232: Middle East Viral Inactivation Market Forecast by Method2021-2031 (US $MN) (COVID - Scenario L)
Figure No 233: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN) (Before COVID)
Figure No 234: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN) (COVID - Scenario V)
Figure No 235: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN) (COVID - Scenario U)
Figure No 236: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN) (COVID - Scenario W)
Figure No 237: Middle East Viral Inactivation Market Forecast by Product 2021-2031 (US $MN) (COVID - Scenario L)
Figure No 238: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 239: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 240: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 241: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 242: GCC Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 243: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 244: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 245: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 246: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 247: South Africa Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 248: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (Before COVID)
Figure No 249: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario V)
Figure No 250: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario U)
Figure No 251: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario W)
Figure No 252: Rest of MEA Viral Inactivation Market Forecast 2021-2031 (US $MN, AGR %) (COVID - Scenario L)
Figure No 253: Danaher Corporation. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 254: Danaher Corporation. (Net Income 2016-2019 (US $Mn, AGR %)
Figure No 255: Merck KGAA (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 256: Merck KGAA (Net Income 2016-2019 (US $Mn, AGR %)
Figure No 257: Parker Hannifin Corporation (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 258: Parker Hannifin Corporation (Net Income 2016-2019 (US $Mn, AGR %)
Figure No 259: Sartorius AG. (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 260: Sartorius AG. (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 261: SGS SA (Total Company Sales 2016-2019 (US $Mn, AGR %)
Figure No 262: SGS SA (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 263: Charles River Laboratories International, Inc (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 264: Charles River Laboratories International, Inc (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 265: Rad Source Technologies, Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 266: Rad Source Technologies, Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 267: Texel, Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 268: Texcell, Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 269: Wuxi Pharmatech (Cayman) Inc. (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 270: Wuxi Pharmatech (Cayman) Inc. (Net Income 2016-2019 (US $Mn, AGR %))
Figure No 271: Viral Inactivated Plasma Systems SA (Total Company Sales 2016-2019 (US $Mn, AGR %))
Figure No 272: Viral Inactivated Plasma Systems SA (Net Income 2016-2019 (US $Mn, AGR %))

Companies Profiled in the Report

1.Merck KGAA

2.Parker Hannifin Corporation

3. Sartorius AG

4. Rad Source Technologies

5. Viral Inactivated Plasma Systems SA

6. Cerus Corporation

7. Clean Cells Inc.

8. Texcell, Inc.

List of Companies Mentioned in the Report:

1. SGS SA
2. Wuxi Pharmatech (Cayman) Inc.
3. Merck KGAA
4. Parker Hannifin Corporation
5. Sartorius AG
6. Rad Source Technologies
7. Viral Inactivated Plasma Systems SA
8. Cerus Corporation
9. Clean Cells Inc.
10. Texcell, Inc.
11. Wuxi Pharmatech (Cayman) Inc.
12. Charles River Laboratories
13. BioReliance
14. Danaher Corporation

List of Organizations Mentioned in the Report:
Food and Drugs Administration
American Cancer Society
World Health Organization
American Hospital Association (AHA)
National Cancer Institute
NIH
CDC
Mayo Clinic